Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

The world desperately needs to be able to believe in AstraZeneca’s coronavirus vaccine, and the never-ending confusion over its clinical data isn’t helping.

The big picture: The extraordinary public dispute between the company and independent experts risks undermining patients' trust, experts said, even if the vaccine turns out to work well.

Driving the news: The independent review board overseeing clinical trials for AstraZeneca’s vaccine, developed in partnership with Oxford University, protested to the NIH after the company said in a press release that the product had proven 79% effective.

  • Those experts told federal officials they thought the company had sliced the data in a way that overstated the vaccine’s effectiveness.
  • One official told The Washington Post that the press release was similar to “telling your mother you got an A in a course, when you got an A in the first quiz but a C in the overall course.”

The other side: AstraZeneca has said it will release a fuller analysis soon, and that it’ll show results consistent with what it claimed in its press release.

What they’re saying: “I think everybody is sort of stunned,” said Jennifer Nuzzo, an epidemiologist at Johns Hopkins. “There are billions of eyeballs on these data.”

  • The public rift between a drug company and independent reviewers is highly unusual. And it’s all the more frustrating, experts noted, because this particular trial was designed in part to help quell some of the uncertainty AstraZeneca caused with its other studies.

“It’s one thing for a drug company or sponsor to bungle this on the first go but this is the second time this company has released information that was inaccurate and confusing, and it’s incredibly frustrating,” said Jonathan Kimmelman, a bioethicist at McGill University.

  • Experts questioned the overall efficacy rate that AstraZeneca had claimed from previous trials, due to the unusual way the company pooled data from multiple research arms.
  • A mistake in the actual administration of those trials also resulted in some patients getting a dosing regimen that the company hadn’t recommended or set out to study.
  • More recently, some European countries have paused their use of the AstraZeneca vaccine because they were worried it might be causing blood clots, although the research hasn't shown any evidence of such a link.

Between the lines: The large, American study — and the FDA authorization that will presumably follow — were supposed to settle the waters.

  • There are no indications that the vaccine is unsafe, and experts believe that whenever the dispute over its efficacy shakes out, it’ll still be a good vaccine and an important tool for the world.
  • If AstraZeneca oversold its findings, it'll create a perception that it needed to juice the numbers. If outside experts overreacted to a minor statistical issue, it'll keep a cloud hanging over an effective vaccine. Either way, it's bad news.

“It’s not doing anyone any favors,” said Natalie Dean, a University of Florida biostatistician and an expert on vaccine clinical trials.

  • Dean withheld judgment on the most recent dust-up, since the full details aren’t yet known. But in the company’s first round of confusing results, she noted, the fact that researchers had to tease out a full picture of the findings over time did more damage than the findings themselves.
  • “If it had just been a straight reporting out of the results, we would have been excited,” she said.

Why it matters: Ultimately, the company will have to present a full set of clinical data to the FDA, and the FDA will conduct a thorough and public review, as it has with the other vaccines.

  • The fear, experts said, is that the confusion will create a general perception that something’s amiss.
  • “The biggest cost is diminished confidence, distrust,” Kimmelman said. “Distrust is leaky.”

What’s next: Ultimately, Kimmelman said, the problem is that too much information about life-and-death medical treatments has been delivered in simple press releases, with little hard data to evaluate their claims.

  • A combination of low-quality research and over-torqued reporting of that research helped create widespread confusion last spring over whether hydroxychloroquine was an effective coronavirus treatment. (It’s not.)
  • A steady drip of leaks and partial data releases also suggested that remdesivir was shaping up to be a much bigger game-changer of a treatment than it has turned out to be.
  • AstraZeneca’s vaccine will probably stand up much better than those two drugs when scientists are able to read real clinical information and conduct a reality check on the company’s press release — but walking back from too-high expectations will only make life harder.

The bottom line: “I'd rather be thinking about the data instead of whether I can trust the data,” Kimmelman said.

Go deeper

Exclusive: Texas nonprofit got massive border contract after hiring Biden official

Migrants attempting to enter the United States from Ciudad Juarez, Mexico. Photo: David Peinado/Xinhua via Getty Images

A Texas nonprofit that recently hired a Biden transition official got a contract worth as much as $530 million to help manage the influx of migrant children at the southern border, Axios has learned.

Why it matters: The contract is by far the largest ever awarded to Family Endeavors. It's potentially worth more than 12 times the group's most recently reported annual budget — a sign of the demand the new work will place on its operations.

8 mins ago - Politics & Policy

Exclusive: $1 million ad buy defends Georgia law to business critics

Illustration: Aïda Amer/Axios

A leading conservative group is targeting the business community with a seven-figure ad buy on CNBC and local TV defending Georgia's new voting law from its corporate critics, Axios has learned.

Why it matters: By focusing on the C-suite through a network it watches, Heritage Action for America is offering a rejoinder to some companies — even Major League Baseball — after they waded so prominently into politics.

10 mins ago - Politics & Policy

Advocates, Democrats plan to push major pot reform

Illustration: Sarah Grillo/Axios

Advocates and lawmakers favoring marijuana reform are trying to capitalize on the social justice movement and COVID-19 economic rebound to legalize and normalize the use of pot.

Why it matters: The supporters are also trying to take advantage of polls showing broad public support — and get ahead of the reality Democrats could lose their control of Congress after the midterm elections next year.